BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26242829)

  • 21. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
    Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
    Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia.
    Nan FY; Gu Y; Xu ZJ; Sun GK; Zhou JD; Zhang TJ; Ma JC; Leng JY; Lin J; Qian J
    Cancer Med; 2021 Aug; 10(15):5283-5296. PubMed ID: 34227248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and prognosis analysis of
    Zhang TJ; Zhang LC; Xu ZJ; Zhou JD
    Aging (Albany NY); 2020 Jun; 12(14):14677-14690. PubMed ID: 32597790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
    Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
    J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
    Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
    Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.
    Lin N; Fu W; Zhao C; Li B; Yan X; Li Y
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):270-277. PubMed ID: 29024628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
    Marcucci G; Metzeler KH; Schwind S; Becker H; Maharry K; Mrózek K; Radmacher MD; Kohlschmidt J; Nicolet D; Whitman SP; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Mar; 30(7):742-50. PubMed ID: 22291079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of DNMT3a gene mutations in acute myelogenous leukemia].
    Qiao C; Sun C; Zhang SJ; Qian SX; Qian XF; Miao KR; Zhu HY; Hong M; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):303-7. PubMed ID: 21518476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Let-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia.
    Zhu XW; Yao DM; Wu DH; Wen XM; Yang J; Guo H; Yang L; Deng ZQ; Zhang YY; Qian W; Lin J; Qian J
    Tumour Biol; 2016 Jan; 37(1):491-501. PubMed ID: 26227220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
    Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
    J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
    Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
    J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NRAS
    Pan L; Liang F; Chen X; Hao Z; Muyey DM; Chen X; Wang H
    Ann Clin Lab Sci; 2023 May; 53(3):389-397. PubMed ID: 37437942
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Zhang TJ; Zhou JD; Zhang W; Lin J; Ma JC; Wen XM; Yuan Q; Li XX; Xu ZJ; Qian J
    Clin Epigenetics; 2018; 10():47. PubMed ID: 29643943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.
    Yuan XQ; Peng L; Zeng WJ; Jiang BY; Li GC; Chen XP
    Medicine (Baltimore); 2016 May; 95(18):e3519. PubMed ID: 27149454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
    Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
    Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
    J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia.
    Qian J; Chen Q; Yao DM; Yang L; Yang J; Wen XM; Zhang YY; Chai HY; Ma JC; Deng ZQ; Lin J
    Int J Clin Exp Pathol; 2015; 8(1):127-36. PubMed ID: 25755699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
    Qu X; Othus M; Davison J; Wu Y; Yan L; Meshinchi S; Ostronoff F; Estey EH; Radich JP; Erba HP; Appelbaum FR; Fang M
    Cancer; 2017 Jul; 123(13):2472-2481. PubMed ID: 28222251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.
    Yang L; Liu Y; Zhu L; Xiao M
    Leuk Lymphoma; 2015; 56(10):2914-22. PubMed ID: 25721756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.